通过Sortase和Click化学开发一个稳定的主要基因相容性复合体 (MHC)
Safak C Uslu1,2, Uk-Jae Lee1, Soheil Tavakolpour1
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
ACS pharmacology & translational science
|June 20, 2024
概括
研究人员开发了一种新的方法,使用排序酶和点击化学来创建稳定的-MHC (pMHC) 分子. 这一进步有助于识别和向T细胞用于癌症免疫治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- T细胞对于抗瘤免疫是至关重要的,通过结合主要基因相容性复合体 (pMHC) 的T细胞受体 (TCR) 识别位.
- TCR-pMHC相互作用往往很弱,需要多重 pMHC 来识别T细胞,目前的方法与不稳定的抗争.
- 在体内应用需要有效的pMHC生成特定的抗原,这是一个重大障碍.
研究的目的:
- 开发一种多功能且高效的方法来产生稳定的质主要基因相容性复合体 (pMHC) 分子.
- 克服当前pMHC四重化技术的局限性,用于识别识别不稳定的T细胞.
- 创建一个强大的平台,用于生成pMHC,以便在个性化免疫疗法中潜在使用.
主要方法:
- 利用排序酶技术在MHC-结槽附近的β2m上引入一个亚齐德点击手柄.
- 具有多糖氨酸链接器和基因点击手柄的工程.
- 采用阿齐德-基因点击化学,以有效地将类蛋白固定在MHC分子上.
主要成果:
- 成功生成了具有特定TCR结合的稳定点击MHC分子.
- 生成的pMHC分子在4°C下,在没有额外的化物的情况下,表现出超过3个月的稳定性.
- 多糖氨酸链接剂在维持pMHC稳定性和TCR亲和力方面被证明优于PEG链接剂.
结论:
- 排序和点击化学方法为pMHC生成提供了一种多功能和高效的方法.
- 这项技术增强了对抗原特异性T细胞的识别和向,改善了对癌症免疫反应的理解.
- 该方法有可能简化个性化免疫疗法的开发.
相关概念视频
Conservative Site-specific Recombination and Phase Variation
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
Antigen Processing Pathways
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...


